You are currently viewing a new version of our website. To view the old version click .

New Drug Delivery across the Blood–Brain Barrier

This special issue belongs to the section “Drug Targeting and Design“.

Special Issue Information

Dear Colleagues,

Drug delivery into the central nervous system (CNS) is modulated by blood–brain interfaces. The blood–brain barrier (BBB), the blood–cerebrospinal fluid barrier (BCSFB), and the blood–arachnoid barrier (BAB) are key interfaces regulating the exchange of substances between the blood, the CSF, and the brain parenchyma. Drug delivery to the CNS can thus be limited due to unfavorable physicochemical properties, efficient active brain to blood carrier-mediated efflux, and/or poor active blood to brain carrier-mediated influx. Several strategies are currently developed to increase CNS drug delivery of small and large molecular weight drugs, including direct administration into the brain parenchyma, methods disrupting BBB integrity, development of specific chemicals or antisense oligonucleotides inhibiting efflux transporter activity, rational drug design decreasing substrate recognition by efflux transporters and/or increasing transport by influx transporters or carrier-mediated transcytosis receptors, and development of nanomedicines and biologics from microbiological origin targeting the BBB and delivering drugs into the brain parenchyma.    

Prof. Dr. Xavier Declèves
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • blood–brain barrier
  • brain interfaces
  • drug delivery
  • neuropharmacology
  • drug transporters
  • nanomedicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Published Papers

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Pharmaceutics - ISSN 1999-4923